ALK-Abelló A/S (ALKBC.XC)

Compare

155.05

0.00

(0.00%)

At close: February 20 at 3:53:26 PM GMT

U.S. FDA Approves Label Expansion for ALK's ODACTRA® (House Dust Mite Allergen Tablet) for Sublingual Use as Immunotherapy to Now Include Children with House Dust Mite Allergy

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the U.S. Food and Drug Administration (FDA) expanded its indication of ODACTRA® (House Dust Mite Allergen Tablet) for the treatment of house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, to now include children ages 5 through 11 years, in addition to patients 12 through 65 years of age.2 ODACTRA is an allergy immunotherapy indicated to treat HDM-induced allergic rhinitis and is administered sublingually as a sma

PR Newswire 3 days ago

AKBLF
FDA approves ODACTRA® for the treatment of house dust mite allergy in young children

ALK (ALKB:DC / OMX: ALK B) today announced that the US Food and Drug Administration (FDA) has approved ALK’s ODACTRA® tablet for use in young children with house dust mite (HDM) allergy. ODACTRA® is now indicated to treat HDM-induced allergic rhinitis, with or without conjunctivitis, in children aged five through 11, in addition to patients aged 12 through 65. ODACTRA® is an allergy immunotherapy (AIT) tablet which dissolves under the tongue and helps patients reduce their allergy symptoms and t

GlobeNewswire 4 days ago

AKBLF
Annual General Meeting in ALK-Abelló A/S on 13 March 2025

ALK (ALKB:DC / OMX: ALK B / AKBLF): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 13 March 2025 at 4:00 PM (CET) at ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 About ALKALK

GlobeNewswire 12 days ago

AKBLF
Annual report 2024: ALK delivers 15% sales growth with profits up 65%

ALK’s (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the 2024 annual report. Following a robust performance in Q4, full-year results were in line with the latest outlook and represent the best results in the history of the company. ALK expects to continue its growth trajectory and earnings improvement in 2025. Q4 2024 highlights (Comparative figures are shown in brackets. Growth rates are stated in local currencies, unless otherwise indicated) Revenue increased by 11% to DKK 1,49

GlobeNewswire 12 days ago

AKBLF
Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its annual report for 2024 in the morning on Wednesday, 19 February 2025. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, where ALK’s management will comment on the results and outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. Live audio webcast The meeting will be audio webcasted liv

GlobeNewswire 19 days ago

AKBLF
ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of ACARIZAX® for the treatment of persistent, moderate to severe house dust mite allergic rhinitis in adults and adolescents. The recommendation paves the way for patients to gain access to ACARIZAX® through the National Health Service (NHS) systems in England, Wales, and Northern Ireland, now making it eligible for general reimbursement. ACARIZAX® is the f

GlobeNewswire last month

AKBLF
3 Stocks Estimated To Be Trading At Discounts Of 26% To 44%

As global markets experience fluctuations with cooling inflation and strong bank earnings propelling U.S. stocks higher, investors are increasingly focused on identifying opportunities amidst these shifting conditions. In this environment, finding undervalued stocks can be a compelling strategy, as they may offer potential value when market sentiment is volatile and certain sectors outperform others.

Simply Wall St. last month

AKBLF

METSA.HE

METSB.HE
3 Stocks That May Be Trading Below Estimated Value

In the current climate, global markets are experiencing volatility with U.S. stocks facing declines due to cautious Federal Reserve commentary and political uncertainties, while European and Asian indices also reflect investor apprehension over interest rate outlooks. Amid these fluctuations, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on market inefficiencies. A good stock in this context is one that...

Simply Wall St. 2 months ago

AKBLF

CSCCF
ALK – Financial calendar for the 2025 financial year

2025 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 22 January 2025: Silent period 19 February 2025: Annual report 2024 13 March 2025 at 4.00 p.m.: Annual General Meeting to be held at ALK Bøge Allé 1 2970 Hørsholm, Denmark Written requests to have specific business transacted at the AGM will be included in the agenda if received by the company on 29 January 2025 at the latest (may be emailed to investor@alk.net) 8 April 2025: Silent period 6 May 2025: Three-month interim report (Q1)

GlobeNewswire 2 months ago

AKBLF
Positive results advance peanut tablet to phase II development

ALK’s peanut tablet shown to be safe and tolerable across multiple doses.Development now advances to phase II for dose finding and efficacy. First patients in phase II to receive first doses imminently. Trial expected to complete in 2026. ALK (ALKB:DC / OMX: ALK B) today announced positive interim results from its phase I/II clinical trial (named ‘ALLIANCE’) for its investigational sublingual immunotherapy (‘SLIT’) tablet for the treatment of peanut allergy. This part of the trial, which involve

GlobeNewswire 2 months ago

AKBLF
ACARIZAX® approved in Europe for treatment of young children

ALK (ALKB:DC / OMX: ALK B) today announced that its European regulatory filing for ACARIZAX® (house dust mite sublingual allergy immunotherapy tablet) in young children aged five to 11 has been approved by the health authorities in 21 EU countries via a type II variation procedure. The first market introductions, including in ALK’s largest market, Germany, are expected to follow over the coming months. The data that formed the basis for the approval includes results from the largest-ever paediat

GlobeNewswire 2 months ago

AKBLF
ALK’s pivotal phase 3 trial in children published in reputable scientific journal

The reputable scientific journal, The Lancet Regional Health – Europe, has published robust results from ALK’s house dust mite sublingual allergy immunotherapy tablet (SLIT-tablet) phase 3 children trial, MT-12, evaluating the efficacy and safety in children (5-11 years) with house dust mite allergic rhinitis.1 With the acceptance for publication, ALK’s MT-12 phase 3 trial has been evaluated by the journal for its methodology, relevance, and clinical implications. This scrutiny helps ensure that

GlobeNewswire 3 months ago

AKBLF
3 Stocks That May Be Trading At A Discount Of Up To 41.4%

In the current global market environment, uncertainty surrounding the incoming Trump administration's policies has contributed to volatility, with U.S. stocks experiencing a partial reversal of recent gains and sector returns showing significant variation. As investors navigate these fluctuations and consider potential policy impacts on corporate earnings, identifying stocks that may be undervalued can offer opportunities for those seeking value investments. A good stock in this context is...

Simply Wall St. 3 months ago

AKBLF

GJNSF

GJNSY
Nine-month interim report (Q3) 2024 (unaudited)

Company release No. 19/2024 ALK delivers 18% organic revenue growth and an operating profit margin of 23% in Q3 Revenue growth was mainly driven by a continued strong momentum in tablet sales and a recovery in Jext® sales. Europe and International markets were key contributors to growth. The operating profit improved in line with ALK’s financial ambitions, and the full-year outlook remains unchanged. Q3 performance highlights Comparative figures for Q3 2023 are shown in brackets. Revenue growth

GlobeNewswire 3 months ago

AKBLF
ARS Pharmaceuticals announces agreement with ALK to commercialize neffy

ARS Pharmaceuticals (SPRY) announced a licensing agreement with ALK-Abello A/S (AKBLF), that provides ALK exclusive rights to commercialize neffy, the first and only needle-free emergency treatment for Type I allergic reactions including anaphylaxis, in Europe, Canada and other geographies outside of the U.S. ARS Pharma retains all rights to neffy in the U.S., and there are no changes to its existing partnerships in Japan, China, Australia and New Zealand. Published first on TheFly – the ultimat

TipRanks 3 months ago

AKBLF

SPRY
ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (“ARS Pharma”, NASDAQ: SPRY). The agreement grants ALK exclusive global rights to the neffy® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers on key elements in ALK’s new strategy Allergy+ and supports ALK’s long-term financial ambitions. Needle-free, nasal delivery of adrenaline has th

GlobeNewswire 3 months ago

AKBLF
Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024

ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its results for the first nine months (Q3) 2024 in the morning of Thursday 14 November 2024. Later same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, where ALK’s management will comment on the results for the first nine months and outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR. Live audio webcast T

GlobeNewswire 3 months ago

AKBLF
ALK Announces U.S. FDA Approval of New AccuTest™ Allergy Skin Testing Devices for Optimized Allergy Testing and Diagnosis

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF), a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies, announced the licensing of a new line of ALK branded allergy skin testing devices and well trays. This new line includes the AccuTest-1™, AccuTest-8™ and AccuTest-10™ Allergy Skin Testing Devices for allergy testing and diagnosis as well as the AccuTest™ 48-well and 60-well allergen trays.

PR Newswire 4 months ago

AKBLF
Six-month interim report (Q2) 2024

Company release No. 16/2024 ALK delivers 21% organic revenue growth with an operating profit margin of 19% in Q2 (unaudited) Revenue growth was driven by a continued strong momentum in tablet sales, and improved performance of injection- and drop-based allergy immunotherapy products. ALK’s European and International markets were key contributors to growth. The increase in operating profit (EBIT) of 189% is in-line with ALK’s financial targets. Full-year outlook has been upgraded. Q2 performance

GlobeNewswire 6 months ago

AKBLF
ALK upgrades its full-year revenue and earnings outlook

ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook has been upgraded to reflect the current performance and outlook for the remainder of the year. Revenue is now expected to grow by 14-16% in local currencies (prev.: 12-15%).The EBIT margin is now expected to improve to 19-21% (prev.: 18-20%) vs. 14% in 2023. The full-year revenue outlook has been upgraded primarily to reflect the strong sales of tablets and injection- and drop-based allergy immunotherapy pro

GlobeNewswire 6 months ago

AKBLF

Performance Overview

Return	ALKBC.XC	OMX Copenhagen 25 Index
YTD	-5.97%	+4.07%
1-Year	+54.43%	-3.85%
3-Year	-77.46%	+7.41%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ALK-Abelló A/S (ALKBC.XC)

U.S. FDA Approves Label Expansion for ALK's ODACTRA® (House Dust Mite Allergen Tablet) for Sublingual Use as Immunotherapy to Now Include Children with House Dust Mite Allergy

FDA approves ODACTRA® for the treatment of house dust mite allergy in young children

Annual General Meeting in ALK-Abelló A/S on 13 March 2025

Annual report 2024: ALK delivers 15% sales growth with profits up 65%

Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025

ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system

3 Stocks Estimated To Be Trading At Discounts Of 26% To 44%

3 Stocks That May Be Trading Below Estimated Value

ALK – Financial calendar for the 2025 financial year

Positive results advance peanut tablet to phase II development

ACARIZAX® approved in Europe for treatment of young children

ALK’s pivotal phase 3 trial in children published in reputable scientific journal

3 Stocks That May Be Trading At A Discount Of Up To 41.4%

Nine-month interim report (Q3) 2024 (unaudited)

ARS Pharmaceuticals announces agreement with ALK to commercialize neffy

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

Invitation to the presentation of ALK’s results for the first nine months (Q3) 2024 on Thursday 14 November 2024

ALK Announces U.S. FDA Approval of New AccuTest™ Allergy Skin Testing Devices for Optimized Allergy Testing and Diagnosis

Six-month interim report (Q2) 2024

ALK upgrades its full-year revenue and earnings outlook

Performance Overview